Change over period: —
NSE · IOLCP
IOL CHEM PH
-13.8% from the 52-week high · +178.2% above the low
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm's APIs portfolio covers various therapeutic categories, such as pain management, anti-diabetic, anti-hypertensive, and anti-convulsant, amongst others. The firm operates through two business divisions: Active Pharma Ingredients (API), and Specialty Chemicals. Its API vertical is engaged in research, developing, and providing various essential products that are used by pharma companies. Its API product portfolio includes Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its Specialty Chemical division includes Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid.
The short version. IOL CHEM PH reported revenue of ₹795 crore for Sep 2026, up 40.0% from a year earlier. Net profit was ₹65 crore (up 116.7% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 62.28% in Sep 2026, up 9.66 points over 8 quarters.
1 · The price
How has the stock traded?
IOL CHEM PH trades 13.8% below its 52-week high and 178.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹795 cr.
Sep 2026 net profit of ₹65 cr.
2.9 pts higher than a year earlier.
Revenue compounded at 1.4% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 795 | 756 | 619 | 580 | 568 | 552 | 528 | 523 |
| Net profit | 65 | 64 | 53 | 21 | 30 | 34 | 31 | 21 |
| Net margin % | 8.2 | 8.5 | 8.6 | 3.5 | 5.3 | 6.2 | 6.0 | 3.9 |
| EPS (₹) | 2.22 | 2.19 | 1.81 | 0.7 | 1.02 | 1.16 | 1.07 | 0.7 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | 2319 | 2079 | 2133 | 2217 | 2184 |
| Net profit | 138 | 101 | 134 | 139 | 168 |
| Net margin % | 5.9 | 4.9 | 6.3 | 6.3 | 7.7 |
| EPS (₹) | 4.69 | 3.44 | 4.58 | 4.74 | 5.71 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 7.6% in Mar 2026; debt to equity is 0.07.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 7.6 | 6.0 | 8.3 | 9.2 |
| Return on capital % | 10.5 | 8.6 | 11.7 | 13.1 |
| EBITDA margin % | 11.9 | 10.7 | 12.0 | 11.2 |
| Net margin % | 5.9 | 4.8 | 6.2 | 6.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 1.4% | — |
| Profit CAGR | -0.4% | — |
4 · The owners
Who holds it, and are they adding?
Up 9.66 pts over 8 quarters.
Up 5.76 pts over 8 quarters.
Up 0.22 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 52.62 | 52.62 | 52.62 | 52.62 | 52.62 | 57.48 | 62.28 | 62.28 | +9.66 |
| FII | 1.49 | 1.47 | 2.59 | 2.25 | 2.08 | 1.72 | 4.87 | 7.25 | +5.76 |
| DII | 0.08 | 0.07 | 0.02 | 0.04 | 0.03 | 0.02 | 0.43 | 0.3 | +0.22 |
| Public | 45.81 | 45.83 | 44.76 | 45.09 | 45.27 | 40.78 | 32.42 | 30.17 | -15.64 |
Mutual fund holdings · Oct 2026
6 schemes hold this stock
4 the month before.
- UNION ACTIVE MOMENTUM FUND2.38% of NAV
- Motilal Oswal BSE Healthcare ETF0.12% of NAV
- Bandhan BSE Healthcare Index Fund0.12% of NAV
- Motilal Oswal BSE 1000 Index Fund0.01% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.01% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for IOL CHEM PH are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about IOL CHEM PH
What is the IOL CHEM PH share price?
IOL CHEM PH (IOLCP) last closed at ₹191.54, up 0.95% on the day. Its 52-week range is ₹68.21 to ₹220.22.
What is the market cap of IOL CHEM PH?
IOL CHEM PH has a market capitalisation of about ₹5,574 crore. Its price-to-earnings ratio is 27.7.
How are IOL CHEM PH's latest results?
IOL CHEM PH reported revenue of ₹795 crore for Sep 2026, up 40.0% from a year earlier. Net profit was ₹65 crore (up 116.7% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 62.28% in Sep 2026, up 9.66 points over 8 quarters.
Who owns IOL CHEM PH?
As of Sep 2026, shareholding was: Promoter 62.28%, FII 7.25%, DII 0.3%, Public 30.17%.
How many mutual funds hold IOL CHEM PH?
6 mutual fund schemes held IOL CHEM PH in October 2026. That compares with 4 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 17 Feb 2026 · Interim Dividend - Rs. 1
- 11 Mar 2025 · Stock Split From Rs.10/- to Rs.2/-
- 18 Feb 2025 · Interim Dividend - Rs. 4
- 16 Feb 2024 · Interim Dividend - Rs. 5
- 17 Feb 2023 · Interim Dividend - Rs. 4
- 15 Feb 2022 · Interim Dividend - Rs. 4
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.